PITTSBURGH, Dec. Thirty (HSMN NewsFeed) — Mylan Inc. (Nasdaq: MYL ) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received final approval from the U.S. Food and Drug Administrati…
Biopharmaceuticals, Generics, FDA, HIV/AIDS
Mylan, Matrix Laboratories Limited, Stavudine, Bristol-Myers Squibb, Zerit
Nail Your Sales Interview with the 30/60/90 Day Sales Plan
If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.Now you can nail your interview with the 30 60 90 Day Sales Plan template with Audio Coaching. This simple tool will help you knock the socks off your interviewer and bury your competition.
To get the details: Click Here
0 Comments on “Mylan’s Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules”
Leave a Comment